Preclinical Data Highlighting Uptake and Enhanced Anti-Tumor Effects of Cellectar’s CLR 131 in Head and Neck Cancer Presented at AACR Annual Meeting Apr 16, 2018
Cellectar Granted Seminal U.S. Patent for Phospholipid-Ether Analogs as Cancer-Targeting Drug Vehicles Mar 27, 2018
Cellectar Biosciences Granted Orphan Drug Designation for CLR 131 to Treat Neuroblastoma Mar 19, 2018
Cellectar Biosciences to Host 2017 Financial Results and Business Update Conference Call on March 22, 2018 Mar 19, 2018
Cellectar Announces Late-Breaking Poster Presentations at AACR 2018 Featuring PDCs and CLR 131 Mar 15, 2018
Phase 1 Clinical Data Demonstrating CLR 124 Uptake in Brain Tumors Accepted for Oral Presentation at the 12th World Congress of the World Federation of Nuclear Medicine and Biology Mar 6, 2018